RxDoctor Payments Data

Olayomi Olonode, NP

Psychiatric/Mental Health · Houston, TXNPI 1316689102

Payments from drug & device makers

$798in general payments, 2019–2025

Across 30 payments — averaging $26.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$385
  • Otsuka America Pharmaceutical, Inc.$136
  • Alkermes, Inc.$131
  • Acadia Pharmaceuticals Inc$73
  • Teva Pharmaceuticals USA, Inc.$39
  • Alpha Cognition USA, Inc.$34

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$207,570
Medicare patients
377
Services billed
2,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$128,777
Chlorpromazine Hcl13$3,202
Memantine Hcl57$2,114
Divalproex Sodium52$1,923
Ziprasidone Hcl14$1,325
Buspirone Hcl67$1,275
Quetiapine Fumarate73$1,258
Aripiprazole19$1,211
Olanzapine35$1,086
Mirtazapine65$1,013
Sertraline Hcl75$997
Clonazepam54$944
Trazodone Hcl75$875
Escitalopram Oxalate41$625
Lorazepam49$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$385$128,77734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →